Category Archives: Molecular Medicine

Dublin, Sept. 18, 2020 (GLOBE NEWSWIRE) -- The "National eHealth Initiatives Advancing Global Precision Medicine Market, 2018-2025" report has been added to ResearchAndMarkets.com's offering.

This research service analyzes the key building blocks for the precision medicine ecosystem to provide strategic imperatives and growth opportunities for key participants.

Key Issues Addressed

The study captures both the global and regional flavors for PM market opportunity realization such as: market projections, drivers and restraints, country readiness index, and major government and commercial initiatives. The study also provides live case studies and innovative business models for leading companies in the PM space.

Precision medicine is transitioning toward wider acceptance, due to mounting payer pressures and regulatory changes that are shifting pharma businesses from prescriptive to more predictive and personalized models. Emergence of value-based reimbursement models and healthcare consumerism trends are helping move the treatment model from one-size-fits-all' to a stratified and outcome-based targeted therapeutics concept called precision medicine' (PM).

Companion diagnostics (CDx) and targeted therapeutics (TRx) are going beyond oncology and spreading more toward therapeutic areas such as infectious diseases, central nervous system (CNS), and cardiovascular diseases. Despite a relatively high success rate for PM R&D assets commercialization in recent years, considerable challenges exist around proving clinical utility and a regulatory and reimbursement framework, which is rigid, decentralized, and non-uniform.

Advances in omics technologies help in identifying molecular targets with the help of molecular insights generated by datasets about the disease pathogenesis. PM informatics is the key component of the PM ecosystem. PM-cognitive analytic platforms capable of leveraging genomic, clinical, financial, and lifestyle data, while delivering actionable clinical insights at the point of care, are gaining market traction. Big Data and Artificial Intelligence (AI) are the key enablers for utilizing the full potential of PM for building predictive models based on multi-omics data, given a big hurdle in the adoption of PM is lack of technology infrastructure.

Genomic sequencing has huge potential to support the COVID-19 outbreak exploration, especially in comprehending the re-emergence of potential COVID-19 outbreaks.

In terms of geographic outlook, although the specific focus on PM research started in the United States and the EU, countries such as Canada, China, Australia, Taiwan, South Korea, Singapore, and Japan have made significant advances in recent years in this area by way of significant investments to develop in-country research and scientific expertise to improve access. Considering the infrastructure requirements for utilizing omics in clinical practice, China and Japan are beating other leading countries in terms of both research initiatives and regulations and infrastructure development.

Key Topics:

Executive SummaryKey Questions This Study Will Answer6 Big Themes for Precision MedicinePrecision Medicine - Regional Market OverviewPrecision Medicine Vendor Landscape by Major Market ClustersPrecision Medicine Readiness of Major CountriesKey InsightsPrecision Medicine in the Wake of COVID-19

Research Scope, Definitions, and SegmentationResearch ScopePersonalized Vs Precision MedicinePrecision Medicine CategoriesPatient Stratification - Data Volume, Sources, and AdoptionPrecision Medicine - Key Segments and Data Sources

Current and Future State of Precision MedicineGlobal Precision Medicine Market - Macro to Micro VisioningChanging Modalities of Innovative DrugsPrecision Medicine in the Late-stage Clinical Trials PipelineMajor Pharmacogenomics BiomarkersPrecision Medicine Vendor Landscape

Precision Medicine Market Projections (2019–2025)Scenario Contingent Projections for Core Precision Medicine SegmentForecast Assumptions for Core Precision Medicine Segment - Optimistic ScenarioForecast Assumptions for Core Precision Medicine Segment - Pessimistic ScenarioCore Precision Medicine Segment - Revenue Forecast Scenario AnalysisCore Precision Medicine Segment - Revenue Forecast by SubsegmentsForecast Assumptions - Core Precision Medicine Key Subsegments

Precision Medicine Cluster Benchmarking by Major CountriesSelect Countries’ Readiness for Precision MedicineFactors Consideration for Precision Medicine Country Readiness IndexCountry Readiness for Precision Medicine - USCountry Readiness for Precision Medicine - EU and UKCountry Readiness for Precision Medicine - APAC

Growth Opportunities in Precision MedicineMajor Growth Opportunities

Opportunity Analysis - CDx and Biomarker-based Targeted Therapeutics (TRx)Growth Opportunity 1 - CDx and Biomarkers-based TRxPrecision Medicine Clinical Trials Trends in Major RegionsTop Areas of Companion Biomarker ResearchNew Clinical Trial Designs in the Era of Precision MedicineSelect Countries’ TRx and CDx Readiness Index

Opportunity Analysis - Genomics Technologies for Precision DiagnosticsGrowth Opportunity 2 - Genomics Technologies for Precision DiagnosticsPrecision Medicine Patient Stratification by Omics/Diagnostic FactorsLevel of Adoption of Select Novel Technologies and ApproachesGenomics Technologies for Precision DiagnosticsSelect NGS Vendor LandscapeSelect Countries’ Omics Research Readiness Index

Opportunity Analysis - Precision Medicine InformaticsGrowth Opportunity 3 - Precision Medicine Informatics SolutionsPrecision Medicine Informatics Market LandscapePrecision Medicine Informatics Market SizeC2A: Xifin - Precision Medicine Informatics for MDxSelect Countries’ eHealth Readiness Index

Key Conclusions

Appendix

For more information about this report visit https://www.researchandmarkets.com/r/lvkzh

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Go here to see the original:
Global Precision Medicine Research Report 2020: Taiwan, Estonia, and Finland Emerging as Key Markets Fueling Growth Opportunities in Precision...

DetailsCategory: Proteins and PeptidesPublished on Friday, 18 September 2020 10:55Hits: 201

- Series A led by Canaan Partners, Samsara BioCapital and The Column Group- Foundational research into cytokine structural biology and immune function licensed from Stanford University- Nils Lonberg joins founding investors on board of directors

MENLO PARK, CA, USA I September 17, 2020 I Synthekine Inc., an engineered cytokine therapeutics company, today announced the closing of an $82 million Series A financing. The financing was co-led by Canaan Partners, Samsara BioCapital and The Column Group, with participation from other undisclosed investors. Synthekine was founded by K. Christopher Garcia, Ph.D., to leverage discoveries showing that cytokines can be tuned to enhance their therapeutic effects.

Synthekine combines strengths in immunology, structural insights on cytokines and multiple engineering technologies to create optimized therapeutics against new and validated cytokine targets for the treatment of cancer and autoimmune disorders. Proceeds from this Series A financing will be used to advance Synthekines lead therapeutic programs into clinical studies, expand its discovery pipeline and hone its proprietary cytokine engineering platforms. The company currently has two lead programs in IND-enabling development: STK-012, an engineered Interleukin-2 (IL-2) partial agonist for the treatment of cancer, and the combination of STK-009 and SYNCAR-001, an orthogonal IL-2 ligand and a CD-19 CAR-T-cell therapy being studied in combination.

Cytokines have a fundamental role in the immune system and represent an enormous opportunity for innovative therapeutics. However, most cytokines broadly activate a wide range of cells that can simultaneously stimulate and suppress the immune system, making drug development against these targets challenging, said Debanjan Ray, chief executive officer of Synthekine. Chris Garcia has shown, for a wide range of therapeutically important cytokines, that cytokine efficacy and toxicity can be decoupled through structure-based protein engineering. These findings mean that many cytokines previously thought to be unsuitable as therapeutics can be transformed into safe and effective drugs. In addition to our highly differentiated IL-2-based programs, we have assembled multiple best-in-class technologies and an accomplished team to develop cytokine therapeutics by engineering them at the molecular level to enhance their activity and selectivity.

Unlocking cytokine therapeutics through unique structural biology insights

Cytokines are small, soluble proteins that are powerful regulators of the immune system and can stimulate a wide range of immune cells, primarily driven by their binding and interaction with cell surface receptors. Most cytokines are pleiotropic, meaning that a given cytokine can exert a range of responses across multiple cell types. Pleiotropy has proven to be a significant obstacle in the development of cytokine therapeutics. Existing cytokine therapeutics, such as aldesleukin (Proleukin) and interferons, demonstrate meaningful efficacy in cancer and other diseases but are limited by significant side effects.

Synthekine has licensed several cytokine programs and platforms from Stanford University. Research conducted in the Garcia lab at Stanford led to insights into the interaction of cytokines and their receptors, allowing researchers to engineer modified cytokines to deliver selective activity to particular cell types of therapeutic interest, giving them the potential for optimized efficacy, a larger therapeutic window and improved safety for patients. This research has been responsible for determining the three-dimensional structures for many different cytokine/receptor complexes, including IL-1, IL-2, IL-4, IL-6, IL-13, IL-15, IL-17, IL-23 and the three different classes of interferons.

A deep preclinical pipeline and proprietary platform

Synthekine is advancing several preclinical programs and innovative platform technologies. These include:

A collaborative company formation effort and seasoned leadership team

The founding members of Synthekines board of directors include Tim Kutzkey, Ph.D., managing partner of The Column Group; Srinivas Akkaraju, Ph.D., founding partner of Samsara BioCapital; and Julie Grant, general partner at Canaan Partners. Synthekine has also appointed biopharma veteran Nils Lonberg as an independent member of its board of directors.

Synthekines executive team is led by Debanjan Ray as chief executive officer. Mr. Ray was previously chief financial officer and head of business development at CytomX Therapeutics, where he was responsible for leading financing efforts and securing multiple strategic collaborations with major pharmaceutical companies that generated more than $400 million in upfront payments and up to $4 billion in milestones. The executive team also includes Martin Oft, M.D., as chief development officer, Rob Kastelein, Ph.D., as head of therapeutic discovery and Gregory Yedinak as senior vice president of technical operations.

Synthekines scientific advisory board is led by its founder, K. Christopher Garcia, Ph.D., professor of molecular and cellular physiology and structural biology at Stanford University School of Medicine, a Howard Hughes Medical Institute (HHMI) investigator and a member of both the National Academy of Sciences and the National Academy of Medicine.

About Synthekine

Synthekine is an engineered cytokine therapeutics company developing disease-optimized treatments. The company uses immunological insights to guide targeted protein engineering to generate transformative medicines for cancer and autoimmune disorders. Using the principles of cytokine partial agonism and immunological specificity, Synthekine designs differentiated therapeutics to be both safe and efficacious. Its lead programs have shown promising efficacy and tolerability in preclinical studies, and it is developing additional cytokine partial agonists that selectively modulate key pathways of the immune system. For more information, visit http://www.synthekine.com.

SOURCE: Synthekine

View original post here:
Synthekine Launches with $82 Million Series A Financing to Advance Pipeline of Engineered Cytokine Therapeutics Optimized for Cancer and Autoimmune...

Fierce Healthcare honors the precision medicine platform for clinical information management capabilities

RALEIGH, NC, UNITED STATES - Sep 16, 2020 - Fierce Healthcare released its annual Fierce Innovation Report this week, naming 2bPrecise the industrys top clinical information management solution. The intent of the awards program, according to Fierce Healthcare, is to showcase organizations that over the past 12 months have demonstrated innovative solutions that have the greatest potential to save money, engage patients, or revolutionize the industry.

Cloud-based, the 2bPrecise platform consumes molecular data from labs and clinical information from the EHR, synthesizing them into a clinical-genomic ontology. The resulting precision medicine insights are delivered to providers within their familiar workflow across any EHR. Plus, the solution is built to interact with evolving knowledge sources and care guidelines.

These unique capabilities enable health systems to leverage precision medicine insights in myriad ways - driving efficient workflows for genomics interventions, extracting population analytics, building cohorts for trial recruitment, enabling participation in research studies and more.

2bPrecise was similarly honored with the MedTech Breakthrough award as Best Overall Genomics Solution earlier this year, and the company received Microsoft Corp.s 2020 Health Innovation Award in the category of Reimagine Healthcare. Industry Wired magazine further recognized 2bPrecise as one of the Top 8 Precision Medicine Companies in the USA this year.

We are honored to receive this latest recognition from Fierce Healthcare, said 2bPrecise CEO Assaf Halevy. The entire 2bPrecise team is driven to create excellent solutions to support clinical decision making within the providers workflow - while simultaneously helping improve outcomes and the patient experience.

Additional winners announced by Fierce Healthcare include Roche (data analytics/business intelligence), Walgreens (digital/mobile health solutions), XSOLIS (financial/operational) and Centivo (population health management/patient engagement).

About 2bPrecise

The cloud-based 2bPrecise platform consumes genetic/genomic data from molecular labs and clinical information from EHRs, synthesizing them into a clinical-genomic ontology. The 2bPrecise Genomic EHR Mentor (GEM) brings the resulting precision medicine insights into a physicians EHR workflow for immediate and timely use. With discrete test results consolidated into an invaluable data set, provider organizations are likewise equipped to drive efficient workflows for genomic interventions, extract population analytics, design clinical intervention programs, build cohorts for trial recruitment, enable participation in research studies and more. Learn more at http://www.2bPreciseHealth.com.

Media Contact

Erica Navar

Account Executive

Aria Marketing (for 2bPrecise)

(909) 538-9541

enavar@ariamarketing.com

Originally posted here:
2bPrecise Wins Industry Innovation Award - Bio-IT World

Within cells, molecules known as transfer RNAs, or tRNAs, play an important but unglamorous workhorse role in keeping the genetic translation process moving along from codes of DNA to functional proteins.

Because they play such a vital role in this translational housekeeping, tRNAs are plentiful.

There are hundreds of tRNA genes in mammalian cells and more than enough backup copies, just in case anything goes wrong. Yet because there are so many tRNAs, theyve been largely overlooked in the search for the roots of disease processes.

University of California San Diego scientists studying tRNAs in mice have now found that a mutation in a tRNA gene calledn-Tr20expressed only in the braincan disrupt the landscape of the entire cell, leading to a chain reaction altering brain function and behavior.

The new researchis described in the journalNeuron.

Study first author Mridu Kapur, a postdoctoral scholar working in Professor Susan Ackermans laboratory, says she and her colleagues found thatn-Tr20plays a role in the delicate balance of excitatory and inhibitory neurotransmission in the brain. A disruption in this balance has been implicated in numerous neurological diseases, including epilepsies and autism spectrum disorders.

tRNAs have generally been overlooked in the hunt for the genetic causes of disease, but recent whole genome sequencing projects have revealed that there are many variations in tRNA sequences in the human population, said Kapur. Our study suggests the enormous potential for tRNA variants to contribute to disease outcomes and phenotypic variability.

The researchers found that a loss ofn-Tr20, one of the members of a five-gene tRNA family, made mice resistant to seizures. While they note that their initial interest in this area came from the idea that a tRNA mutation could subsequently influence other gene mutations, their results not only confirm their speculations that tRNA mutations can influence other mutations, but indicate that these mutations alone can also alter brain function.

You can imagine its like a seesawif you push either way you can have problems, said Ackerman, a member of the Section of Neurobiology, Department of Cellular and Molecular Medicine and investigator at the Howard Hughes Medical Institute. Keeping balance of these two opposing forces is essential for normal function. Shifting one way or another can lead to neurological diseases. Its becoming well accepted in the autism spectrum disorder field that what we are really seeing is an imbalance of excitatory/inhibitory neurotransmission.

Ackerman says part of the reason tRNAs have been overlooked in disease investigations is because researchers commonly concentrate on mutations in unique genes. A member of a large family such asn-Tr20typically gets tossed in the genetic garbage can because they are too similar to one other.

We never knew a mutation in a multi-copy tRNA gene could do anything like this, said Ackerman. These findings make you think about people who have diseases with variable symptoms and how much this class of overlooked genes could be playing a role in their disease. So were seeing this go from a behavior, such as seizure, all the way to the molecular underpinnings causing them.

The researchers say the results are likely the tip of the iceberg and are now turning their attention to studying tRNA links to disease in tissues outside the brain.

Reference: Kapur et al. (2020).Expression of the Neuronal tRNA n-Tr20 Regulates Synaptic Transmission and Seizure Susceptibility. Neuron.DOI: https://doi.org/10.1016/j.neuron.2020.07.023.

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Read the original post:
Mutation in Housekeeping tRNA Linked to Autism - Technology Networks

About the position

At the Faculty of Medicine and Health Sciences, we have a vacancy for a 100% permanent position as Professor/Associate Professor in Medicine (Obesity and Metabolism).

The position is at theDepartment of Clinical and Molecular Medicine.

You willreportto the head of department.

Duties of the position

The appointee is expected to teach within their relevant expertise across all study programmes at the Faculty.

The person appointed must comply with the decisions about changes due to developments in the subject area, and the organizational changes that may result from decisions regarding the university's activities.

Required selection criteria

The position of Professorwithin obesity and metabolism requires that you meet the criteria in theRegulations concerning appointment and promotion to teaching and research posts section 1-2.

In addition to formal qualifications in teaching at university level, you must document

For appointment as a professor, an academic level conforming to establishednational standardsis required

The position of Associate Professor within obesity and metabolism requires that you meet the criteria in theRegulations concerning appointment and promotion to teaching and research posts section 1-4.

You will be expected to deliver high-quality teaching at undergraduate and postgraduate levels, and undertake supervision of Masters and Doctoral candidates. Evaluation of these skills will be based on documented experience and relevant teaching qualifications. Applicants with teaching experience at university level are preferred. Quality and breadth of the teaching qualifications will be evaluated.

NTNU is committed to following evaluation criteria for research quality according toThe San Francisco Declaration on Research Assessment - DORA.This means that we pay special attention to the quality and professional breadth of these works. We also consider experience from research management and participation in research projects.

You must document relevant basic competence forteaching and supervision at university/higher education-level. If this cannot be documented, you are required to complete an approved course in university teaching within two years of commencement. NTNU offers qualifying courses.

It is a prerequisite that within three years of appointment, new employees who do not speak a Scandinavian language can demonstrate skills in Norwegian or another Scandinavian language equivalent to level three in thecourse for Norwegian for speakers of other languages at the Department of Language and Literature at NTNU.

Please see theRegulations concerning appointment and promotion to teaching and research posts for general criteria for the position.

Preferred selection criteria

Personal characteristics

In the assessment of the best qualified applicant, we will emphasize education, experience and personal suitability as well as your motivation for the position.

We offer

Salary and conditions

In a position as professor (code 1013) you will normally be remunerated from gross NOK 704 900,- to NOK 900 000,- per year,depending on qualifications and seniority. From the salary, 2% is deducted as a contribution to the Norwegian Public Service Pension Fund.

In a position as associate professor (code 1011) you will normally be remunerated from gross NOK 573 100,- to NOK 704 900,- per year,depending on qualifications and seniority. From the salary, 2% is deducted as a contribution to the Norwegian Public Service Pension Fund.

The engagement is to be made in accordance with the regulations in force concerning State Employees and Civil Servants, and the acts relating to Control of the Export of Strategic Goods, Services and Technology. Candidates who by assessment of the application and attachment are seen to conflict with the criteria in the latter law will be prohibited from recruitment to NTNU. After the appointment you must assume that there may be changes in the area of work.

It is a prerequisite that you can be present at and accessible to the institution on a daily basis.

About the application

The application and supporting documentation must be in English.

Please note that applications are only evaluated based on the information available on the application deadline. You should ensure that your application shows clearly how your skills and experience meet the criteria which are set out above.

If, for any reason, you have taken a career break or have had an atypical career and wish to disclose this in your application, the selection committee will take this into account, recognizing that the quantity of your research may be reduced as a result.

The application must include:

Joint works will be considered. If it is difficult to identify your contribution to joint works, you must attach a brief description of your participation.

Your application will be considered by an expert committee and the most suitable applicants will be invited to interview and to deliver a lecture.

General information

A good working environment is characterized by diversity. We encourage qualified candidates to apply, regardless of their gender, functional capacity or cultural background. NTNU wishes to increase the proportion of women in its academic positions, and women are therefore encouraged to apply.

As an employee at NTNU, you must at all times adhere to the changes that the development in the subject entails and the organizational changes that are adopted.

Under the Freedom of Information Act (offentleglova), your name, age, position and municipality may be made public even if you have requested not to have your name entered on the list of applicants.

If you have any questions about the position, please contact head of department Torstein Baade R, telephone +47 99 61 40 25, emailtorstein.ro@ntnu.no. If you have any questions about the recruitment process, please contact Yngve Lorentzen, e-mail:yngve.lorentzen@ntnu.no

Please submit your application and supporting documentation via jobbnorge.no.

Application deadline: 15.09.2020

The city of Trondheimis a modern European city with a rich cultural scene. Trondheim is the innovation capital of Norway with a population of 200,000. The Norwegian welfare state, including healthcare, schools, kindergartens and overall equality, is probably the best of its kind in the world. Professional subsidized day-care for children is easily available. Furthermore, Trondheim offers great opportunities for education (including international schools) and possibilities to enjoy nature, culture and family life and has low crime rates and clean air quality.

NTNU - knowledge for a better world

The Norwegian University of Science and Technology (NTNU) creates knowledge for a better world and solutions that can change everyday life.

The Faculty of Medicine and Health Sciences (MH) is one of NTNUs largest faculties with about 1800 employees (

1300 full-time equivalents). The Facultys main activities are education and research in close integration with St Olavs Hospital. For further information, see:https://www.ntnu.edu/mh.

Deadline15th September2020EmployerNTNU - Norwegian University of Science and TechnologyMunicipalityTrondheimScopeFulltimeDurationPermanentJobbnorge ID186952

Read the original here:
Professor/Associate Professor in Medicine Obesity and Metabolism job with NORWEGIAN UNIVERSITY OF SCIENCE & TECHNOLOGY - NTNU | 223116 - Times...

Newswise MicroRNAs (miRNAs) have recently been addressed as novel mediators of cellcell communication, being secreted from cells, and are found in many different biological fluids. Such characteristics also make miRNA potential disease biomarkers. Alterations in miRNA expression have been linked to pathological features and these characteristics make miRNA potential disease biomarkers.

In a review article published in the International Journal of Molecular Sciences Special Issue Crosstalk between MicroRNA and Oxidative Stress in Physiology and Pathology 2.0, authors from the Sbarro Health Research Organization (SHRO), at the Center for Biotechnology, Temple University, and the University of L'Aquila, Italy, focused on miRNAs and their role in mitochondrial dysfunction in aging-related neurodegenerative diseases. The article, titled MicroRNAs Dysregulation and Mitochondrial Dysfunction in Neurodegenerative Diseases, explores the potential of both as diagnostic biomarkers and therapeutic targets. These aspects may have important implications for the design of new drugs and therapeutic interventions for these progressive and incurable diseases.

The ms points towards the roles of microRNAs (miRNAs) in mitochondrial dysfunction and neurodegeneration, says Annamaria Cimini of the University of L'Aquila, lead author of the review.

It appears clear that any neurodegenerative disease is characterized by specific miRNAs, with the consequent downregulation or up-regulation of specific genes, says Antonio Giordano, M.D., Ph.D., Founder and Director of the Sbarro Institute for Cancer Research and Molecular Medicine and the Sbarro Health Research Organization (SHRO). However, each condition analyzed shares some miRNA with the others, thus indicating an overlapping of some pathways. This is conceivable if the common presence of oxidative stress and mitochondrial impairment in diverse diseases is considered, Giordano concludes.

The authors would like to acknowledge support from the Ken and Ann Douglas Charitable Foundation.

About the Sbarro Health Research OrganizationThe Sbarro Health Research Organization (SHRO) is non-profit charity committed to funding excellence in basic genetic research to cure and diagnose cancer, cardiovascular diseases, diabetes and other chronic illnesses and to foster the training of young doctors in a spirit of professionalism and humanism. To learn more about the SHRO please visitwww.shro.org

See the original post:
Understanding Neurodegenerative Disease Such as Alzheimers and ALS by Examining the Overlap of microRNAs, Oxidative Stress, and Mitochondria...

WARSZAWA, Poland, Aug. 25, 2020 /PRNewswire/ --On September 30, 2020, opinion leaders in virology and epidemiology will participate in the International Conference COVID-19.

The event will bring together more than 150 specialists: doctors, professors, scientists, leading researchers of the Ebola vaccine, and other viruses. Among the speakers at the conference are Nobel Prize winner in Physiology and Medicine, Australian virologist Peter Doherty and Nobel Prize winner in Chemistry Michael Levitt.

Deputy Director-General of the World Health Organization Zsuzsanna Jakab will make a welcoming speech at the opening of the conference.

Also, speakers at the conference will be:

Oyewale Tomori, Nigeria - Redeemer's University, former President of the Nigerian Academy of Sciences, has studied viral infections including Ebola, yellow fever and Lassa fever.

Pedro Simas, Portugal - The Institute of Molecular Medicine (IMM) at the University of Lisbon, one of the creators of the reusable mask that disables coronavirus upon contact with fabric

Polly Roy, UK - London School of Hygiene and Tropical Medicine, Officer of the Order of the British Empire for service in Virus research.

Alla Mironenko, Ukraine - Gromashevsky Institute of Epidemiology and Infectious Diseases of the NAMS of Ukraine, Doctor of Science, 30 years experience in the field of infectious diseases.

Anupam Varma, India - President of the World Society for Virology, former President of the Indian Virology Society, Honorary Scientist of INSA Emeritus.

The event will be held as online broadcasts on YouTube and Facebook.

The first broadcast will start on September 30 at 6:00 GMT. The conference will be broadcasted in the format of two-hour sessions. Each session will bring together 15 speakers and will end with a block of questions from viewers and participants. One hour break between broadcasts will take place.

In total there will be 10 live broadcasts, the conference will last 30 hours and will end on October 1 at 11:00 GMT.

The final session summing up the event will start on October 1 at 12:00 GMT.

From October 2, 2020, all the video records of the sessions will be available on the conference website and the event channel on YouTube.

The conference is being organized by the Foundation for the support of International Projects based in Warsaw, Poland.

The media are welcome to cooperate with the organizers of the conference.

The partners of the conference will be able to talk to the participants by video call.

More detailed information about the conference and its participants is available on the project website https://www.education-forum.com/ru/covid.

In order to realize any of the 17 goals of sustainable development of the world, including defeating Coronavirus infection (COVID-19), we need to develop a quality education today. Today, COVID-19 does not defeat us, but makes us stop - the virus stops the growth of the global economy, and the global educational and medical community forces us to look for a solution and, most importantly, unite in finding a solution to defeat COVID-19.

The unification of the global medical community in the fight against COVID-19 once again confirms the correctness of the path we have chosen to achieve all the goals of sustainable development of the world.

This press release was issued through 24-7PressRelease.com. For further information, visit http://www.24-7pressrelease.com.

SOURCE COVID-19 International Conference

https://www.education-forum.com/ru/covid

Read more here:
World-leading Virologists to Speak at COVID-19 International Conference - PRNewswire

The Global Bioelectric Medicine Market research report primarily aims to hint at opportunities and challenges in the Global industry. The report also underscores potential risks, threats, obstacles, and uncertainties in the market and helps clients in intuiting them precisely and operating their business accordingly. The report covers an extensive span of the global Bioelectric Medicine market ranging from historical and current events to futuristic stich of the market.

Click the link to get a Sample Copy of the Report:

https://www.marketinsightsreports.com/reports/08262258324/global-bioelectric-medicine-market-size-status-and-forecast-2020-2026/inquiry?source=&Mode=48

The report presents the market competitive landscape and a corresponding detailed analysis of the major vendor/key players in the market. Top Companies in the Global Bioelectric Medicine Market: Medtronic, Abbott, Boston Scientific Corporation, Cochlear, Sonova Holding, Livanova, Biotronik, Nevro, Second Sight Medical Products, Electrocore

Technology is changing the world and bioelectric medicine is the fore front of technology revolution in medical science. The history of the pharmaceutical industry is based on therapies that target the molecular mechanisms. bioelectric medicine has a different drug therapies that are based on electrical pulses instead of a drug to trigger the body. Bioelectric medicine develops stimulate nerves and activation sensor technology to regulate biological functions and diseases treated by combining biotechnology, neuroscience, molecular medicine, electronics and computing technology could change the future of therapy for various diseases. Drug bioelectric action through targeted mechanisms of action to treat the disease. Although the concept of using bioelectric medicine to treat patients has been about a decade, technological advances are driving the market to grow in the near future. bioelectric medicine is a field in which the device is made for treating various kinds of diseases such as rheumatoid arthritis, diabetes, paralysis and cancer as well.

This report segments on the basis of Types:

Implantable Cardioverter Defibrillators

Cardiac Pacemakers

Spinal Cord Stimulators

Cochlear Implants

Deep Brain Stimulators

Transcutaneous Electrical Nerve Stimulators

Vagus Nerve Stimulators

Sacral Nerve Stimulators

Retinal Implants

Other Electrical Stimulators

Split On the basis of Applications:

Hospitals

Research Institutes

Individual Users

Inquire for Discount:

https://www.marketinsightsreports.com/reports/08262258324/global-bioelectric-medicine-market-size-status-and-forecast-2020-2026/discount?source=&Mode=48

Regional Analysis:

For comprehensive understanding of market dynamics, the global Bioelectric Medicine Market is analyzed across key geographies namely: United States, China, Europe, Japan, South-east Asia, India and others. Each of these regions is analyzed on basis of market findings across major countries in these regions for a macro-level understanding of the market.

Important Features that are under Offering and Key Highlights of the Reports:

Detailed overview of Market

Changing market dynamics of the industry

In-depth market segmentation by Type, Application etc.

Historical, current and projected market size in terms of volume and value

Recent industry trends and developments

Competitive landscape of Market

Strategies of key players and product offerings

Potential and niche segments/regions exhibiting promising growth

The report has 150 tables and figures browse the report description and TOC:

https://www.marketinsightsreports.com/reports/08262258324/global-bioelectric-medicine-market-size-status-and-forecast-2020-2026?source=&Mode=48

What are the market factors that are explained in the report?

Key Strategic Developments: The study also includes the key strategic developments of the market, comprising R&D, new product launch, M&A, agreements, collaborations, partnerships, joint ventures, and regional growth of the leading competitors operating in the market on a global and regional scale.

Key Market Features: The report evaluated key market features, including revenue, price, capacity, capacity utilization rate, gross, production, production rate, consumption, import/export, supply/demand, cost, market share, CAGR, and gross margin. In addition, the study offers a comprehensive study of the key market dynamics and their latest trends, along with pertinent market segments and sub-segments.

Analytical Tools: The Global Bioelectric Medicine Market report includes the accurately studied and assessed data of the key industry players and their scope in the market by means of a number of analytical tools. The analytical tools such as Porters five forces analysis, feasibility study, and investment return analysis have been used to analyze the growth of the key players operating in the market.

Finally, Bioelectric Medicine Market report is the believable source for gaining the Market research that will exponentially accelerate your business. The report gives the principle locale, economic situations with the item value, benefit, limit, generation, supply, request and Market development rate and figure and so on. This report additionally Present new task SWOT examination, speculation attainability investigation, and venture return investigation.

Note: All the reports that we list have been tracking the impact of COVID-19. Both upstream and downstream of the entire supply chain has been accounted for while doing this. Also, where possible, we will provide an additional COVID-19 update supplement/report to the report in Q3, please check for with the sales team.

We Also Offer Customization on report based on specific client Requirement:

Free country Level analysis for any 5 countries of your choice.

Free Competitive analysis of any 5 key market players.

Free 40 analyst hours to cover any other data point.

About Us:

MarketInsightsReports provides syndicated market research on industry verticals including Healthcare, Information and Communication Technology (ICT), Technology and Media, Chemicals, Materials, Energy, Heavy Industry, etc. MarketInsightsReports provides global and regional market intelligence coverage, a 360-degree market view which includes statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact Us:

Irfan Tamboli (Head of Sales) Market Insights Reports

Phone: + 1704 266 3234 | +91-750-707-8687

[emailprotected] | [emailprotected]

Excerpt from:
Bioelectric Medicine Market Competitive Analysis and Research Report 2020 to 2026 - Owned

Visit the News Hub

School of Medicine to become 1 of 10 sites under new Centers for Research in Emerging Infectious Diseases

Washington University School of Medicine in St. Louis is one of 10 sites and a coordinating center forming the Centers for Research in Emerging Infectious Diseases, funded by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health (NIH). The centers are a coordinated network with collaborators in different regions across the globe where emerging and re-emerging infectious disease outbreaks have proven likely to occur.

Researchers at Washington University School of Medicine in St. Louis are establishing a new international collaboration that aims to help scientists prepare for the next pandemic and, perhaps, provide insight into the current one.

The School of Medicine is one of 10 sites and a coordinating center forming the Centers for Research in Emerging Infectious Diseases, funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). Washington Universitys center will be supported by a five-year, $8.1 million grant.

The Centers for Research in Emerging Infectious Diseases (CREID) is a coordinated network with centers that will each have collaborators in different regions across the globe where emerging and re-emerging infectious disease outbreaks have proven likely to occur. The Washington University-led center includes researchers at La Jolla Institute for Immunology in San Diego and international collaborators in China, Hong Kong, Nepal and Ethiopia. In recent years, these regions have seen the emergence of multiple dangerous viruses, including H5N1 influenza, SARS, MERS and, most recently, SARS-CoV-2, the virus that causes COVID-19.

We want to be able to respond quickly and effectively to the emergence of a new infectious disease, said David Wang, PhD, principal investigator of the new center at Washington University. If we can understand the source of the infection, how it spreads and how it affects people, we have a better shot at preventing a new infectious disease from becoming a major threat to global public health.

Multidisciplinary teams of investigators will conduct surveillance of potential sources of new diseases and the local populations at risk of infection. The researchers will study transmission, disease progression, and immunologic responses in the host, and will develop diagnostic tests and animal models of the new diseases for improved detection of important emerging pathogens and the methods by which they spread.

Such information could help predict which new infectious diseases are at highest risk of reaching pandemic status and aid in efforts to understand the new disease and prevent its spread.

In addition to Wang, a professor of molecular microbiology, and of pathology & immunology, key researchers at Washington Universitys center include Michael S. Diamond, MD, PhD, the Herbert S. Gasser Professor of Medicine; Jacco Boon, PhD, an associate professor of medicine; and Scott A. Handley, PhD, an associate professor of pathology & immunology.

The international centers will monitor local populations for the most common red flags of an emerging infection: respiratory disease, inflammation of the brain, and unexplained fever. The researchers will study patient samples to look for new viruses or other microbes with the potential to cause disease. At the same time, investigators will survey local livestock, mosquitoes and ticks to help identify the potential origins of viruses that could be infecting people in a particular region.

The Washington University researchers will focus on the molecular biology and genetics of emerging viruses and on developing animal models, such as mice and other rodents, to help study potentially dangerous viruses, understand how they spread and set the stage for developing treatments.

If we find a new virus that we want to prioritize, we will develop diagnostic tests, and tools to study the virus and will begin to develop treatments, such as therapeutic antibodies, Wang said. We could use our animal models to test possible new drugs. We also will fine tune plans so that we are quick to respond to new emerging outbreaks, such as SARS-CoV-2, first reported in Wuhan, China.

Weve prioritized studies of COVID-19 at the university, Wang added. Were sequencing the genomes of SARS-CoV-2 viruses to understand the transmission and evolution of the virus that is circulating in the St. Louis region. Were also trying to understand how the proteins that the virus makes contribute to the severity of the infection.

The new centers are prioritizing the study of families of viruses that have shown the most potential to impact humans, including coronaviruses (SARS-CoV and MERS-CoV), paramyxoviruses (measles and respiratory syncytial virus), flaviviruses (West Nile, Zika and dengue) and alphaviruses (chikungunya virus), among others.

There are clear sets of viral families that we are most concerned about because they have the highest likelihood of causing major disease in humans, Wang said. At the same time, were definitely looking for everything with our surveillance studies. Every viral family has the potential to be highly dangerous. We hope this program will help identify those infectious diseases most likely to cause major problems, so we can take steps to lessen the impact.

For more information, visit: https://creid-network.org

This work is supported by the NIAID of the NIH, grant number U01AI151810.

Washington University School of Medicines 1,500 faculty physicians also are the medical staff of Barnes-Jewish and St. Louis Childrens hospitals. The School of Medicine is a leader in medical research, teaching and patient care, ranking among the top 10 medical schools in the nation by U.S. News & World Report. Through its affiliations with Barnes-Jewish and St. Louis Childrens hospitals, the School of Medicine is linked to BJC HealthCare.

Read more:
Identifying emerging diseases focus of new international collaboration - Washington University School of Medicine in St. Louis

Thursday, August 27, 2020

In this episode, Foley PartnersJudy WaltzandAntoinette Konskitalk withEdward Abrahams, the President of the Personalized Medicine Coalition, to discuss the issues facing personalized medicine and how the concepts underpinning the field may be applied to diagnose and treat COVID-19.

We encourage you to listen to thepodcast in its entirety.

Following is a transcript of this podcast. Please feel free to download aPDF version here.

Please note that theinterview copy below is not verbatim. We do our best to provide you with a summary of what is covered during the show. Thank you for your consideration, and enjoy the show!

Personalized or precision medicine is the field of medicine that finds the best treatment for each patient at the right time. Physicians use diagnostic tests, medical history, circumstances, and values, as well as information from prior patient therapies, to prevent disease and develop targeted therapies that can expedite a patient's treatment and recovery.

The Personalized Medicine Coalition, or PMC, is an advocacy and educational group that represents innovators, scientists, patients, providers, and payers to promote the understanding and adoption of personalized medicine concepts, services, and products. Dr. Edward Abrahams is the president of the PMC and has charted its growth from its original 18 founding members in 2004 to more than 200 members today.

I am pleased to have Ed as our guest to explore issues facing personalized medicine and how its concepts and emerging research may be applied to diagnose and treat COVID-19. Ed, thank you so much for being with us here today. Did I hit the mark on precision medicine? Is there anything you would like to add by way of introduction to yourself or the PMC?

I think you have defined personalized medicine very well indeed. Let me begin by noting, as you just did, that I have never met a patient who did not prefer getting the right medication the first time, rather than going through a process of trial and error because the right diagnosis could not be made in advance of selecting the right therapy.

The good news is that we have many more molecular diagnostics today to target the right treatments to the right patients at the right time, as is often said. But personalized medicine also promises lower costs for systems that incorporate the tests and treatments underpinning the field into their clinical work streams. This is very important. By becoming more efficient with targeted therapeutics and avoiding costly interventions that don't work, personalized medicine can help these systems save money, and, at the same time, provide better outcomes for individual patients.

In other words, and this is terribly important in today's context of constricted resources for health care, with personalized medicine, we can enjoy the benefits of innovation and reduce costs. But we have to be smart about how we develop these opportunities. At present, we have only anecdotal evidence that personalized medicine can deliver both clinical and economic benefits, which is why PMC is doing the research to demonstrate that even if individual therapies come with high price tags, as many in fact do, they can and will produce cost savings if we target them to only those patients who will benefit.

That, in brief, is the real promise of personalized medicine. We believe personalized medicine can provide tremendous value, not only to patients, but also to the systems and countries that in fact have the courage to implement it.

Thank you so much for that explanation and background on personalized medicine and how it is being used today to treat and prevent disease. Ed, for me, one of the highlights of the year is the publication of PMC's annual report that summarizes the key advances the industry has made over the past year. When will the 2020 edition be released, and can you give us a preview of what to expect?

Within the next eight weeks, the Personalized Medicine Coalition will publish the sixth edition ofThe Personalized Medicine Report. We used to call itThe Case for Personalized Medicine, but we now believe that the case has been made.

The report is our effort to define the field by explaining personalized medicine's opportunity, documenting its status, and discussing the challenges it faces. It's a widely read report that is written for laymen, particularly policymakers at federal agencies and on Capitol Hill.

The sixth edition will, for example, show that in 2008, there were only five personalized medicines, which we define as therapeutics with biomarker strategies on their labels, on the market. Today, there are over 250, so you can see there's been enormous progress over these past 10 years or so.

While most of these products are in oncology, we have also seen progress in other indications as well, including cardiovascular illness, depression, and especially rare diseases. The report will also show that today there are 75,000 genetic testing products on the market, up from fewer than 66,000 in 2016. In other words, this is an exploding field.

Also new in this report are discussions of how advanced analytics, artificial intelligence, and machine learning are yielding new insights about how other biological and environmental factors, in addition to genetics, influence a patient's disease risk and response to various treatments, thus opening the door to preventive medicine, one of personalized medicines most important if as yet unrealized promises.

The report documents how, by targeting effective treatments to those patients who benefit, personalized medicine can achieve key goals for patients and health systems. It can shift the emphasis in medicine from reaction to prevention with emerging technologies like liquid biopsies, which may be able to detect cancer before any symptoms occur. This is tremendously important and a great promise. It may reduce trial-and-error prescribing, which patients would absolutely love.

Personalized medicine can also cut the number of adverse drug reactions, which right now are the third or fourth largest cause of death in the United States. It can use cell-based or gene therapy to replace or circumvent molecular pathways associated with disease, thereby offering cures where none had existed before. It can reveal additional targeted uses for medicines and drug candidates. It will obviously increase patient adherence to treatment, as patients will be more likely to stay on medications that don't have dangerous side effects, for example.

Personalized medicine will also reduce high-risk invasive procedures, which it already has done in say, kidney transplants, for example. It will help move patient-physician engagement toward patient-centered care. And finally, as I mentioned, it could and should reduce the overall cost of health care.

The report makes the argument that outstanding challenges in regulation, reimbursement, and clinical adoption slow our efforts to capitalize on advances made possible by personalizing treatments. Overcoming these obstacles, as we write, will require a collaborative effort to keep up with the pace of progress in science and technology. And this is in fact the overall mission of the Personalized Medicine Coalition.

At the end of the dayand you mentioned this a bit in your commentsfor personalized medicine to be a success and available to patients, it has to be adopted by the clinicians. How does that happen, and are there obstacles to that success?

This is a key thrust of the Personalized Medicine Coalition because we are learning that clinical adoption is a much slower process than patients want and expect. For example, PMC will publish a study this week documenting that medically appropriate genomic testing is quite inconsistent across the United States.

That means, for example, that some patients in cancer are not getting available treatments they need. The study shows that coverage and reimbursement strategies are not the only barriers to personalized medicine, as you might expect. Other barriers include lack of awareness among providers and patients, not to mention socioeconomic factors, including distance and access issues.

In medicine, it doesn't necessarily follow that if you build it, they will come. There are many mediators along the way from discovery and development to adoption. We also know from another PMC-commissioned study of the value of genomic testing in cancer care, for example, that many patients who are eligible for effective targeted therapies, as determined by genomic sequencing of their tumor, still do not receive the best treatment option based on the results.

This practice gap can be attributed to the limitations in the availability and interpretation of test results, sample processing constraints, limited access to targeted therapies, and especially lagging awareness of the rapidly evolving field of personalized medicine among physicians and other providers.

We demonstrate in this study that if all patients who were eligible to receive a targeted treatment actually received it, the cost-effectiveness of genomic sequencing, which is sometimes alleged to be too high, would significantly improve. In short, along with public policy, we know that the downstream issues focused on clinical adoption are extremely important and must be addressed.

We are in a continuing debate with respect to drug pricing in the United States. How does that debate impact the future of personalized medicine and how would you address or make some recommendations as to how we price our drugs?

That's a very important question because as you know, the drug pricing debate has gripped public attention. But we are not considering all ramifications. The debate has particular implications for the development of personalized medicines, which tend to be more expensive but may together have a positive impact on the health care system and on overall costs.

We have to ensure that innovative products remain accessible, including to those who cannot afford them. But we also have to be careful not to remove the incentives to discover and develop those products in the first place, which I am afraid that price controlsno matter how they are implementedwould do. That is to say, they would stifle innovation. Drug development is a risky business. There are no guarantees. If we move or decrease the financial incentive to find new cures to unmet medical needs, it follows that we're going to see fewer interventions.

Late last month, President Trump issued an executive order to tie the prices paid for physician-administered drugs, many of which are personalized medicines, to those that are paid in other countries. That may be politically popular because those other countries pay less. But the policy, if implemented, will have disastrous unintended consequences for the development of say, new cell-based therapies, gene therapies, and targeted medicines that are only now reshaping health care in ways no one thought possible ten years ago.

This is so because there are incentives in place to encourage the development of groundbreaking therapies. It's important to understand that when a pharmaceutical company invests in, say, finding a one-shot cure for spinal muscular atrophya rare and debilitating disorder that affects fewer than 25,000 people in the United Statesit does so without any guarantee of success, and it does so also with very high up-front costs that must be recovered. If the company that develops the cure cannot get a return on its investment, it's unlikely to take these big risks upon which patients depend. Long story short, patients will suffer and the costs of providing carenot curesfor those patients will remain higher than they could be.

I'd like your opinion on a topic of current urgent and global concern. Today, we are challenged medically and economically with the COVID-19 pandemic. How have the principles of personalized medicine been applied to diagnosing and treating COVID-19?

I actually believe that the principles of personalized medicine that emphasize stratified responses, even when it comes to public health, have significant implications for diagnosing and treating COVID-19. Those principles, I believe, should inform future interventions to stem this terrible pandemic that has already killed over 170,000 people in the United States alone.

I don't think these principles are being adequately considered as part of the debate. PMC looks forward to introducing those principles, because they're so very important if we're going to effectively address this pandemic.

First, we have been very slow to develop and deploy real-time diagnosticsthe backbone of personalized medicine. These diagnostics give us the tools to determine who is at risk, so we don't have to put in place one-size-fits-all public health responses, including closing down whole economies, when that might not be necessary if we knew who had the disease or who was likely to get the disease.

To date, we have not been able to target long-term prevention and treatment plans to the most at-risk populations, which would be enormously helpful in reopening economies, which we would obviously like to do sooner than later.

Second, and equally important, we know that the coronavirus expresses itself differently among different populations. For example, older men, racial and ethnic minorities, and those with particular underlying conditions seem to be more vulnerable to disease. It behooves us, therefore, to understand the molecular and environmental reasons for this differentiated response, and to develop and deploy therapies and vaccines that are targeted to those who are in need.

Today, we are looking for one-size-fits-all solutions because there's an urgency to find one. But eventually, scientists in my opinion are going to recognize that, because not everyone responds the same, different medicines are going to have to be developed to treat COVID-19 and other viruses.

We've already seen this in AIDS, and so I don't think the coronavirus is going to be different. We have to be really smart about how we address this pandemic. By the way, on September 3rd, PMC is organizing a virtual seminar, titledCOVID-19 and Personalized Medicine: Current Status and Lessons Learned. It is free, and if you want to register, you can do so on ourwebsite.

Ed, thank you so much for being with us today, and as we wrap up, I'd like to invite you to make any closing remarks or comments on the topics we covered today.

I'd really like to thank you both for your loyal support to the Personalized Medicine Coalition, and for giving me the opportunity to discuss these very important issues with your audience. I hope people will pay attention to personalized medicine. We believe it represents the future, and we also believe that if we invest in it, if we come together collaboratively as a community, we can have a health care system that we deserve based upon the developments in science and technology, which have never been more promising. Again, thank you for your attention, and I look forward to working with you and everybody on this podcast to move this field forward. It's not going to happen by itself.

Read more:
COVID-19 & Healthcare: Personalized Medicine is the Future - The National Law Review